RETRACTED: Gravina et al. The Small Molecule Ephrin Receptor Inhibitor, GLPG1790, Reduces Renewal Capabilities of Cancer Stem Cells, Showing Anti-Tumour Efficacy on Preclinical Glioblastoma Models. Cancers 2019, 11, 359

Abstract

Full text

The journal retracts the article, “The Small Molecule Ephrin Receptor Inhibitor, GLPG1790, Reduces Renewal Capabilities of Cancer Stem Cells, Showing Anti-Tumour Efficacy on Preclinical Glioblastoma Models” [1], cited above.

Following publication, concerns were brought to the attention of the Editorial Office regarding the integrity of an image presented in this publication [1].

Adhering to our standard procedure, an investigation was conducted by the Editorial Office and the Editorial Board that identified indications of partial overlap between the sub-images in Figure 1C (T24 and T28) published in [1] and overlap between Figure 5B published in [1] and Figure 4B published in [2], produced by a similar author group presenting different experimental conditions. While the authors provided replacement images during the investigation, the Editorial Board found the explanations regarding the duplicated data insufficient to warrant a correction. Consequently, the Editorial Board has lost confidence in the reliability of the findings and decided to retract this publication [1], as per MDPI’s retraction policy (https://www.mdpi.com/ethics#_bookmark30).

This retraction was approved by the Editor-in-Chief of the Cancers journal.

The authors did not provide a comment on this decision.

The corresponding author, Claudio Festuccia, takes full responsibility for the concerns raised and clarifies that the other co-authors were not directly involved in the duplication of the figures in question.